Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Janet Lo, M.D.

Co-Author

This page shows the publications co-authored by Janet Lo and Kathleen Fitch.
Connection Strength

3.479
  1. Pro-Inflammatory Interleukin-18 is Associated with Hepatic Steatosis and Elevated Liver Enzymes in People with HIV Monoinfection. AIDS Res Hum Retroviruses. 2021 05; 37(5):385-390.
    View in: PubMed
    Score: 0.229
  2. Measures of Adipose Tissue Redistribution and Atherosclerotic Coronary Plaque in HIV. Obesity (Silver Spring). 2020 04; 28(4):749-755.
    View in: PubMed
    Score: 0.215
  3. Anti-Inflammatory Interleukin 10 Inversely Relates to Coronary Atherosclerosis in Persons With Human Immunodeficiency Virus. J Infect Dis. 2020 02 03; 221(4):510-515.
    View in: PubMed
    Score: 0.214
  4. Low vitamin D is associated with coronary atherosclerosis in women with HIV. Antivir Ther. 2019; 24(7):505-512.
    View in: PubMed
    Score: 0.199
  5. Diet Quality Is Low and Differs by Sex in People with HIV. J Nutr. 2019 01 01; 149(1):78-87.
    View in: PubMed
    Score: 0.199
  6. I-FABP Is Higher in People With Chronic HIV Than Elite Controllers, Related to Sugar and Fatty Acid Intake and Inversely Related to Body Fat in People With HIV. Open Forum Infect Dis. 2018 Nov; 5(11):ofy288.
    View in: PubMed
    Score: 0.197
  7. Brief Report: Statin Effects on Myocardial Fibrosis Markers in People Living With HIV. J Acquir Immune Defic Syndr. 2018 05 01; 78(1):105-110.
    View in: PubMed
    Score: 0.190
  8. Aspartame Intake Relates to Coronary Plaque Burden and Inflammatory Indices in Human Immunodeficiency Virus. Open Forum Infect Dis. 2017; 4(2):ofx083.
    View in: PubMed
    Score: 0.177
  9. Subclinical myocyte injury, fibrosis and strain in relationship to coronary plaque in asymptomatic HIV-infected individuals. AIDS. 2016 09 10; 30(14):2205-14.
    View in: PubMed
    Score: 0.169
  10. Serum oxidized low-density lipoprotein decreases in response to statin therapy and relates independently to reductions in coronary plaque in patients with HIV. AIDS. 2016 Feb 20; 30(4):583-90.
    View in: PubMed
    Score: 0.163
  11. Effects of statin therapy on coronary artery plaque volume and high-risk plaque morphology in HIV-infected patients with subclinical atherosclerosis: a randomised, double-blind, placebo-controlled trial. Lancet HIV. 2015 Feb; 2(2):e52-63.
    View in: PubMed
    Score: 0.151
  12. Noncalcified coronary atherosclerotic plaque and immune activation in HIV-infected women. J Infect Dis. 2013 Dec 01; 208(11):1737-46.
    View in: PubMed
    Score: 0.138
  13. Increased coronary artery calcium score and noncalcified plaque among HIV-infected men: relationship to metabolic syndrome and cardiac risk parameters. J Acquir Immune Defic Syndr. 2010 Dec; 55(4):495-9.
    View in: PubMed
    Score: 0.113
  14. Decreased respiratory quotient in relation to resting energy expenditure in HIV-infected and noninfected subjects. Metabolism. 2009 May; 58(5):608-15.
    View in: PubMed
    Score: 0.102
  15. Baseline and post-treatment hepatitis C NS5A resistance in relapsed patients from a multicentric real-life cohort. Antivir Ther. 2018; 23(4):307-314.
    View in: PubMed
    Score: 0.093
  16. Assessment of Obesity and Cardiometabolic Status by Integrase Inhibitor Use in REPRIEVE: A Propensity-Weighted Analysis of a Multinational Primary Cardiovascular Prevention Cohort of People With Human Immunodeficiency Virus. Open Forum Infect Dis. 2021 Dec; 8(12):ofab537.
    View in: PubMed
    Score: 0.061
  17. Corrigendum to: Patterns of Antiretroviral Therapy Use and Immunologic Profiles at Enrollment in the REPRIEVE Trial. J Infect Dis. 2021 02 03; 223(2):352.
    View in: PubMed
    Score: 0.057
  18. Differential Plasma Protein Regulation and Statin Effects in Human Immunodeficiency Virus (HIV)-Infected and Non-HIV-Infected Patients Utilizing a Proteomics Approach. J Infect Dis. 2020 08 17; 222(6):929-939.
    View in: PubMed
    Score: 0.056
  19. Patterns of Antiretroviral Therapy Use and Immunologic Profiles at Enrollment in the REPRIEVE Trial. J Infect Dis. 2020 07 09; 222(Suppl 1):S8-S19.
    View in: PubMed
    Score: 0.055
  20. Comparison of visceral fat measurement by dual-energy X-ray absorptiometry to computed tomography in HIV and non-HIV. Nutr Diabetes. 2019 02 25; 9(1):6.
    View in: PubMed
    Score: 0.050
  21. Mild renal impairment is associated with calcified plaque parameters assessed by computed tomography angiography in people living with HIV. AIDS. 2019 02 01; 33(2):219-227.
    View in: PubMed
    Score: 0.050
  22. Relationship of visceral and subcutaneous adipose depots to markers of arterial injury and inflammation among individuals with HIV. AIDS. 2019 02 01; 33(2):229-236.
    View in: PubMed
    Score: 0.050
  23. Assessing statin effects on cardiovascular pathways in HIV using a novel proteomics approach: Analysis of data from INTREPID, a randomized controlled trial. EBioMedicine. 2018 Sep; 35:58-66.
    View in: PubMed
    Score: 0.049
  24. Sex Differences in Subclinical Coronary Atherosclerotic Plaque Among Individuals With HIV on Antiretroviral Therapy. J Acquir Immune Defic Syndr. 2018 08 01; 78(4):421-428.
    View in: PubMed
    Score: 0.048
  25. Insulin-like growth factor 1 inversely relates to monocyte/macrophage activation markers in HIV. AIDS. 2018 04 24; 32(7):927-932.
    View in: PubMed
    Score: 0.047
  26. Epicardial adipose tissue volume and cardiovascular risk indices among asymptomatic women with and without HIV. Antivir Ther. 2018; 23(1):1-9.
    View in: PubMed
    Score: 0.046
  27. Differential relationships of hepatic and epicardial fat to body composition in HIV. Physiol Rep. 2017 Oct; 5(19).
    View in: PubMed
    Score: 0.046
  28. Proprotein Convertase Subtilisin/Kexin 9 Levels in Relation to Systemic Immune Activation and Subclinical Coronary Plaque in HIV. Open Forum Infect Dis. 2017; 4(4):ofx227.
    View in: PubMed
    Score: 0.046
  29. Reduced ovarian reserve relates to monocyte activation and subclinical coronary atherosclerotic plaque in women with HIV. AIDS. 2016 Jan 28; 30(3):383-93.
    View in: PubMed
    Score: 0.041
  30. RAAS Activation Is Associated With Visceral Adiposity and Insulin Resistance Among HIV-infected Patients. J Clin Endocrinol Metab. 2015 Aug; 100(8):2873-82.
    View in: PubMed
    Score: 0.039
  31. Plaque burden in HIV-infected patients is associated with serum intestinal microbiota-generated trimethylamine. AIDS. 2015 Feb 20; 29(4):443-52.
    View in: PubMed
    Score: 0.038
  32. Soluble CD163 is associated with shortened telomere length in HIV-infected patients. J Acquir Immune Defic Syndr. 2014 Dec 01; 67(4):414-418.
    View in: PubMed
    Score: 0.037
  33. 2013 American College of Cardiology/American Heart Association and 2004 Adult Treatment Panel III cholesterol guidelines applied to HIV-infected patients with/without subclinical high-risk coronary plaque. AIDS. 2014 Sep 10; 28(14):2061-70.
    View in: PubMed
    Score: 0.037
  34. Increased coronary atherosclerosis and immune activation in HIV-1 elite controllers. AIDS. 2012 Nov 28; 26(18):2409-12.
    View in: PubMed
    Score: 0.033
  35. Relation of body composition to body mass index in HIV-infected patients with metabolic abnormalities. J Acquir Immune Defic Syndr. 2008 Feb 01; 47(2):174-84.
    View in: PubMed
    Score: 0.023
  36. Dietary fat intake and relationship to serum lipid levels in HIV-infected patients with metabolic abnormalities in the HAART era. AIDS. 2007 Jul 31; 21(12):1591-600.
    View in: PubMed
    Score: 0.023
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.